Table 1.

Reactivity of anti-CD36 sera in solid-phase ELISA (PakPlus) and/or MAIPA assays using three mAbs against CD36 (FA6-152, GZ-608, and GZ-70)

Anti-CD36 serum number	Age (yr)/ sex	Diagnosis	Optical density
			PakPlus	mAb FA6-152	mAb GZ-608	mAb GZ-70
1	44/M	Healthy donor	0.989	0.293	0.667	0.516
2	50/F	Healthy donor	1.138	0.438	1.003	0.733
3	50/M	Hypercholesterolemia	0.663	0.168	0.655	0.540
4	69/F	Anemia	0.791	0.200	0.797	0.341
5	41/M	Thoracic aortic aneurysm	0.569	0.145	0.255	0.290
6	22/M	T-lymphoblastic cell tumor	1.812	1.615	3.143	2.654
7	35/F	Myelodysplastic syndromes	0.923	0.431	0.754	0.696
8	35/F	FNAIT (abortion)	0.835	0.189	0.624	0.481
9	30/F	FNAIT (abortion)	1.551	0.020	0.550	0.440
10	36/F	FNAIT (thrombocytopenia)	0.990	0.200	0.355	0.375
11	46/M	Alcoholic cirrhosis	2.292	0.340	0.384	0.367
12	44/F	Acute leukemia	0.745	0.185	0.582	0.411
13	35/F	FNAIT (thrombocytopenia)	0.257	0.289	0.543	0.633
14	56/M	Myelodysplastic syndrome	0.827	0.199	0.143	0.158
		Cut-off*	> 0.160	> 0.200	> 0.200	> 0.200
			14/14 (100.0%)	6/14 (42.9%)	13/14 (92.9%)	13/14 (92.9%)

*The cut-off for each assay was determined by analyzing AB sera from healthy blood donors (N=8). The reaction was considered positive when the result was greater than the cut-off value (mean value±3 SDs).

Negative reactions are indicated in italics.

Abbreviations: MAIPA, monoclonal antibody immobilization of platelet antigens; mAbs, monoclonal antibodies; FNAIT, fetal/neonatal alloimmune thrombocytopenia.